ApoB and Lp(a): the heart tests your annual physical may miss

ApoB and Lp(a) are two blood tests that can reveal cardiovascular risk a standard cholesterol panel misses. ApoB counts the particles that carry cholesterol into artery walls, and large studies suggest it tracks risk more completely than LDL cholesterol. Lp(a) is a mostly inherited particle that raises risk regardless of lifestyle, affects about 1 in 5 people, and the American Heart Association says every adult should have it measured at least once.

Picture the founder who ran a half marathon last spring, eats reasonably well and was told at his last physical that his cholesterol "looked fine." His father had a heart attack at 52, which he mentions to no one because it feels like ancient history. Nothing on his lab report would have flagged the inherited risk he may be carrying.

Most annual physicals include neither test. For a founder who has put off the physical twice and assumes "my cholesterol was fine," that gap is worth closing.

Why a normal cholesterol panel can miss real heart risk

A standard lipid panel reports total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides. LDL cholesterol, the "bad cholesterol" number, measures how much cholesterol is being carried inside LDL particles. It is a useful number. It is also an indirect one.

What actually damages arteries is the particles. Cholesterol-carrying lipoproteins such as LDL slip into the artery wall and get stuck, and that is how plaque starts. Each of those potentially harmful particles carries exactly one apolipoprotein B molecule on its surface. So measuring ApoB is essentially counting the particles, while LDL cholesterol measures their cargo.

Most of the time those two numbers move together. Sometimes they do not. Two people can have the same LDL cholesterol, but one of them carries it in many smaller particles. That person has more particles bumping into artery walls, and a higher ApoB, even though the standard panel looks identical.

This is common in exactly the metabolic profile that long hours, poor sleep and a high-stress job tend to produce: higher triglycerides, a bit of weight around the middle, blood sugar creeping up. We cover how chronic stress pushes those numbers in what chronic stress does to a founder's body.

What does an ApoB test show that LDL doesn't?

The strongest recent evidence comes from the UK Biobank. A 2025 study in the European Journal of Preventive Cardiology followed 375,544 people who had no cardiovascular disease at baseline and were not taking lipid-lowering medication. The researchers looked for people whose ApoB and LDL cholesterol disagreed, defined as a gap of more than 10 percentile points between where each person ranked on the two measures.

The results were clear in direction. People whose ApoB was discordantly high had a hazard ratio of 1.11 for cardiovascular events, about 11% higher risk. People whose ApoB was discordantly low had a hazard ratio of 0.87, about 13% lower risk. In other words, when the two numbers disagreed, risk followed ApoB. The authors concluded that "ApoB is a more comprehensive marker of cardiovascular risk than LDL-C." They also found that part of the extra risk in the high-ApoB group was linked to triglyceride-rich particles, the kind that rise with the metabolic pattern described above.

Evidence quality: very large and prospective, which is about as good as observational data gets. It is still observational, so it shows that ApoB predicts risk, not that targeting ApoB rather than LDL changes outcomes. That is a question for trials and for your physician.

An 11% shift may not sound dramatic. Think of it as what the standard panel was quietly mispricing. For the person with discordantly high ApoB, the report said "fine" and the risk said otherwise.

What is Lp(a), and why is it different?

Lipoprotein(a), usually written Lp(a) and pronounced "L-P-little-a," is a cholesterol-carrying particle in the blood. What sets it apart is where it comes from. The American Heart Association says plainly that "Your level is mostly inherited."

That has three practical consequences.

First, it is common and invisible. About 1 in 5 people worldwide have high Lp(a), and it does not show up on a standard lipid panel. You can be lean, fit and eating well and still carry it.

Second, you cannot out-train it. The AHA notes that "lifestyle changes don't lower Lp(a) levels." That can feel discouraging, but the same page adds that you can still lower your overall risk of heart disease, which is exactly why knowing your number matters. If one risk factor is fixed, the ones you can move (blood pressure, ApoB, smoking, sleep, activity) carry more weight.

Third, because it is mostly genetic and stays fairly stable, one test is usually enough. The AHA recommends that "every adult be tested at least once in their lifetime," particularly people with a family history of premature heart disease or familial hypercholesterolemia.

What counts as high?

The AHA gives two thresholds. A level of 125 nmol/L (50 mg/dL) or higher is an elevated risk level. At 250 nmol/L (100 mg/dL) or higher, risk may double. Labs report Lp(a) in either unit, and the two are not directly interchangeable, so read your result against the unit the lab used and go over it with your physician.

How many people actually get tested?

Very few, even though testing is growing. A 2025 analysis in JACC: Advances looked at Lp(a) testing across more than 300 million people in the United States from 2015 to 2024. Over the whole decade, 728,550 distinct patients were tested, or 0.2% of the U.S. population.

The annual number of people tested grew from 14,471 in 2015 to 309,806 in 2024. That is real progress, and it is still a rounding error next to the roughly 1 in 5 people who carry high Lp(a). The authors describe "persistently low rates of testing with significant regional and demographic variation."

Put those two numbers side by side and the math is uncomfortable. If 20% of people have high Lp(a) and a fraction of 1% have ever been tested, most of the people carrying it do not know.

What the evidence says, and what it doesn't

Strong: Lp(a) is common, mostly inherited, not lowered by lifestyle, and higher levels are associated with higher cardiovascular risk. The AHA recommends testing every adult at least once.

Strong, observational: In a very large prospective cohort without heart disease, ApoB captured cardiovascular risk more completely than LDL cholesterol, particularly when the two disagreed.

Less settled: Whether managing to an ApoB target instead of an LDL target improves outcomes for everyone. How best to treat people whose main risk factor is high Lp(a). These are active areas of research and clinical judgment.

Not what it means: A high ApoB or Lp(a) is a risk factor, not a diagnosis of heart disease. A normal result does not cancel out smoking, high blood pressure or a strong family history.

Any decision about medication belongs with a physician who knows your full history. If you have chest pain, shortness of breath on exertion or high blood pressure readings, see a physician promptly rather than waiting for a lab result.

What a founder can actually do this week

Ask for the two tests by name. At your next physical, or by booking one now, ask your physician whether an ApoB test and a one-time Lp(a) test make sense for you. Both are ordinary blood draws. Mention any family history of early heart attack or stroke, because that changes how the results are read.

Find out your family history. Lp(a) is mostly inherited. A parent or grandparent who had a heart attack or stroke young is a reason to test, and a high result in you is a reason for close relatives to ask about testing too.

Get the whole picture in one place. ApoB and Lp(a) are most useful alongside blood pressure, blood sugar markers, triglycerides, smoking status and waist measurement. Ask your physician to put them together into an overall risk estimate rather than reading each number in isolation.

Work the levers you control. If Lp(a) comes back high, it raises the stakes on everything else. Regular movement, a consistent sleep window, not smoking and managing blood pressure are all within reach. Sleep is the one founders cut first. The routine in meditation for sleep for executives is a practical place to start.

Bring three questions. Keep them short so they survive a 15-minute appointment. Given my history, should my ApoB be checked, and what would you consider a good number for me? Has my Lp(a) ever been measured, and if not, can we do it once now? If either comes back high, what would change in my plan, and when would we retest? The answers tell you as much about the quality of your care as the labs do.

Put a date on it. The most common failure mode is not a bad result. It is the physical that keeps getting pushed back a quarter at a time. Book it before the next board meeting fills the calendar.

Knowing your numbers without living in them

There is a trap on the other side of this. Some founders, once they start measuring, cannot stop: retesting every month, refreshing lab portals at midnight, turning a risk factor into a source of chronic stress that works against the very system they are trying to protect.

The goal is to know your numbers, act on them with a physician and then get back to your life. Being able to hold uncertain information calmly, without either ignoring it or spiraling on it, is a trainable skill. It is much of what we work on at Cinder, where private 1:1 coaching focuses on stress regulation and the kind of steady attention that makes good decisions possible under pressure. Our piece on why founders are hiring meditation coaches explains what that looks like.

Two tests worth one conversation

Your annual physical was designed for the average patient. ApoB and Lp(a) fill two specific gaps in it: one counts what the standard panel only estimates, and the other finds an inherited risk the standard panel cannot see. Both are simple blood tests. Ask about them, understand them with your physician and use what you learn.

Apply for private coaching

Sources

• Lipoprotein(a), American Heart Association, accessed 2026
• Impact of LDL-C and apolipoprotein B level discordance and associated lipoprotein particle alterations on cardiovascular outcomes in a large primary prevention population, European Journal of Preventive Cardiology (via UK Biobank), 2025
• Lipoprotein(a) Testing Trends in the United States 2015-2024: An Analysis of 300 Million Individuals, JACC: Advances (via PMC), 2025